AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01007461
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium Chloride (NaCl) will be administered in the same manner as the experimental drug.
Trial: NCT04214639
Drug: IDP-126 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP-126 Gel applied topically to the face once daily for 12 weeks.
Trial: NCT04214639
Drug: IDP-126 Vehicle Gel
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
Trial: NCT01940536
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00086099
Drug: Idarubincin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubincin (12mg/m2) and ara-C(N-18)
Trial: NCT01433263
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01504334
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo（without active ingredient） tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week for both groups.
Trial: NCT01523483
Drug: placebo vaginal capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo capsules placed (soy lecithin and sunflower oil) into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
Trial: NCT00581867
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01929668
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00547950
Drug: :Deng Zhan Sheng Mai Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule，0.18g，2＃，po，Bid\*1year.
Trial: NCT02266875
Drug: hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02266875
Drug: standard saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01107470
Drug: hFSH（Fostimon）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
Trial: NCT01107470
Drug: hFSH（Fostimon）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
Trial: NCT01633944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo Buccal Film twice daily
Trial: NCT02694224
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dose dense Cyclophosphamide (600 mg/m2) together with Epirubicin each 2 weeks x 4 doses with GMCSF after Paclitaxel
Trial: NCT01872572
Drug: Subcutaneous RB006 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous RB006 0.5 mg/kg
Trial: NCT01872572
Drug: Subcutaneous RB006 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous RB006 1.0 mg/kg
Trial: NCT01872572
Drug: Subcutaneous RB006 3.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous RB006 3.0 mg/kg
Trial: NCT01872572
Drug: Subcutaneous RB006 2.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Arm 1: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration~* Arm 2: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration.
Trial: NCT01872572
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00909636
Drug: ABT-333
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm description for more information
Trial: NCT00909636
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm description for more information
Trial: NCT02488629
Drug: SCB01A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study is a single arm, open-label, Phase II trial
Trial: NCT05236309
Drug: Jing-Guan-Fang(JGF) : Chinese herbal decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use 100ml JGF decoction per day as a preventive measure for patients with COVID-19.
Trial: NCT01464320
Drug: ABT-614
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active
Trial: NCT01464320
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03912233
Drug: TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablets for oral administration.
Trial: NCT03912233
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos matched to VX-121, TEZ, and VX-561 for oral administration.
Trial: NCT03806426
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg capsule, two 500mg capsules to be taken twice daily for 24 months
Trial: NCT02727881
Drug: Placebo Ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Ophthalmic solution
Trial: NCT00175903
Drug: Valproate Extended Release
RxNorm normalized name: valproate Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of 1000-2000 mg ER oral tablets, 300 mg and 500 mg twice daily.
Trial: NCT03056703
Drug: Acetylsalicylic acid (Aspirin, BAY1019036)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One Fast Release Tablet containing 1000 mg acetylsalicylic acid
Trial: NCT03056703
Drug: Acetylsalicylic acid (Aspirin, BAY1019036)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two Fast Release Tablets containing 500 mg acetylsalicylic acid each
Trial: NCT00654628
Drug: ezetimibe (+) simvastatin
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks.
Trial: NCT01873989
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02270255
Drug: 1% Xylocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5ml of 1% Xylocaine
Trial: NCT04453384
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1
Trial: NCT00622427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets for every night for 2 weeks
Trial: NCT01560624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00028886
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00028886
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01386983
Drug: 5ARI
RxNorm normalized name: 5-alpha reductase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride or Finasteride
Trial: NCT01386983
Drug: 5ARI + AB
RxNorm normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
Trial: NCT03930992
Drug: standard treatment in HIV positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 Arm (HIV+): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
Trial: NCT03930992
Drug: standard treatment in HIV negative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 Arm (HIV-): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
Trial: NCT03343600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos 2 tablets daily
Trial: NCT03437226
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Arm: 1 x 5 ml (1 vial) of placebo levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
Trial: NCT00848744
Drug: Formulation A
RxNorm normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation A will be applied to the randomly-assigned single (left or right) side of the face twice daily.
Trial: NCT00848744
Drug: Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation B will be applied to the randomly-assigned single (left or right) side of the face twice daily.
Trial: NCT03585140
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg per day orally, before breakfast
Trial: NCT00649454
Drug: Metaglip® Tablets 5 mg/500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5/500mg, single dose fasting
Trial: NCT01564706
Drug: florbetapir F 18
RxNorm normalized name: Florbetapir F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection, 370MBq (10mCi), single dose
Trial: NCT03106532
Drug: PHP-201 0.25% ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 drops daily, 28 days
Trial: NCT03106532
Drug: PHP-201 0.5% ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 drops daily, 28 days
Trial: NCT03106532
Drug: Placebo ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 drops daily, 28 days
Trial: NCT05651347
Drug: Melatonin 10 MG
RxNorm normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin 10 mg tablets will be administered three times a day, up to a maximum of 30 mg daily
Trial: NCT02388295
Drug: AZD3241
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: AZD3241 administered for 12 weeks orally as a tablet.
Trial: NCT02388295
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match AZD3241 administered for 12 weeks orally as a tablet.
Trial: NCT04387097
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: postoperative drip-infusion of remifentanil
Trial: NCT03388593
Drug: rhNRG-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
Trial: NCT03388593
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
Trial: NCT01059383
Drug: VECAM 40/300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule, orally, once daily at bedtime.
Trial: NCT01943552
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline
Trial: NCT04274803
Drug: Intralipid, 20% Intravenous Emulsion
RxNorm normalized name: Intralipid, 20% intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intralipid 20% (Frezenius, Clayton, NC, USA) in a dose of 4 ml diluted in 250 ml 0.9% regular saline to be infused IV and to be repeated every 2 weeks all over the pregnancy.
Trial: NCT03118830
Drug: Recombinant Follicle Stimulating Hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily sc rFSH (Gonal-f; Merck Serono , Darmstadt, Germany) injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done.
Trial: NCT04302064
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplontersen-matching placebo administered SC
Trial: NCT00830193
Drug: D5W Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo (D5W) in 100 cc D5W (pre-CT dose) or 2.5 g NAC or placebo in 50 cc D5W (post-CT doses).
Trial: NCT03752723
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: i.v.
Trial: NCT00117689
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For a minimum of 3 months
Trial: NCT02282904
Drug: Cyclophosphamide post transplant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg/d IV infused over 90 minutes. Day +3 and +4
Trial: NCT02282904
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 14.5 mg/kg IV over one hour Day -6 and -5
Trial: NCT00514020
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given through a vein over 5 minutes and then continuously over 46 hours on days 1 and 15.
Trial: NCT00514020
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: through a vein over 2 hours on days 1 and 15.
Trial: NCT01092962
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2mg/kg/day during 12 weeks (cumulative dose 148mg/kg)
Trial: NCT04560894
Drug: SCT510
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive SCT510 intravenously，15mg/kg，d1，Q3w
Trial: NCT00645463
Drug: CP-945,598
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg CP-945,598 + 240 mg MR Diltiazem
Trial: NCT00645463
Drug: CP-945,598
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg CP-945,598 alone
Trial: NCT01055678
Drug: EF5
RxNorm normalized name: Hb 76(EF5), Met-thr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An infusion of EF5, a fluorinated 2-nitroimidazole, will be administered using the recommended dose of 21mg/kg one day prior to surgical procedure.
Trial: NCT02107872
Drug: REGN1500
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02107872
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02472613
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was given for 12 consecutive weeks.
Trial: NCT02472613
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine was given at a dose of 20 mg/day for12 consecutive weeks.
Trial: NCT04334564
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos were controls.
Trial: NCT01825369
Drug: IV L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT02415790
Drug: E2027 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2027 matching placebo capsule will be administered.
Trial: NCT00756548
Drug: BLI850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multi-dose preparation for oral administration prior to colonoscopy
Trial: NCT01305512
Drug: SPARC1028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPARC1028 administration as 30-minute intravenous infusion once a week for 3 weeks, followed by 1 week of rest
Trial: NCT02484027
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be randomly assigned to receive 2 different therapies for the first 3 days of hospitalization: no statins (non-statin-therapy group) or to immediately receive rosuvastatin orally at a dose of 20mg daily (statin-therapy group). From the fourth day onward, rosuvastatin 10 mg daily will be administered in all patients for 1 year
Trial: NCT00367211
Drug: PN 200 tablets (500 mg naproxen and 20 mg omeprazole)
RxNorm normalized name: esomeprazole 20 MG / naproxen 500 MG [Vimovo]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00367211
Drug: Naproxen 500 mg tablets (PN 200 minus omeprazole)
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01495481
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful
Trial: NCT02194348
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02491385
Drug: iv-PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv-PCA setting was fentanyl 20 mcg/ml, bolus/lock out time/basal, 0.5 ml/15 min/0.5 ml.
Trial: NCT03594058
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
Trial: NCT02645916
Drug: Danggui-Sayuk-Ga-Osuyu-Saenggang-tang
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Trial: NCT00552760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet at bedtime for up to 6 months
Trial: NCT01496911
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single oral dose
Trial: NCT03022981
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOF/VEL fixed-dose combination (FDC) 400/100 mg tablets or SOF/VEL FDC 200/50 mg tablets (based on swallowability assessment)
Trial: NCT03022981
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOF/VEL FDC 200/50 mg oral granules
Trial: NCT05453994
Drug: H. pylori eradication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPIs-based Antimicrobial agents for H. pylori eradication
Trial: NCT03327064
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This matches the UAB30 in appearance. Frequency of dosing will be daily for 28 days.
Trial: NCT00003558
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01782235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01860937
Drug: cyclophosphamide based chemotherapy regimens
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00885365
Drug: tobramycin / Bramitob
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg/4ml solution, via a nebuliser, over a 4-week treatment in a twice-daily regimen
Trial: NCT00885365
Drug: tobramycin / TOBI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg/5ml solution administered via nebuliser, over a 4-week treatment in a twice-daily regimen
Trial: NCT04328506
Drug: CM082 tablet (test product)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test product(T)：100mg CM082 tablet manufactured by Betta Pharmaceuticals
Trial: NCT00253565
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04328506
Drug: CM082 tablet (reference product)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product(R)：100mg CM082 tablet manufactured by Catalent Pharma Solutions
Trial: NCT03463772
Drug: In vitro maturation
RxNorm normalized name: Vitron-C Reformulated Jul 2016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled ovarian stimulation protocol will not performed in this group patients. Transvaginal ultrasound scanning was examined on natural cycle to monitor the follicle size in group B participants. Oocyte retrieval was scheduled once the endometrium had reached at least 6 mm in thickness and there was no follicle larger than 10 mm. After oocyte retrieval, the COCs will be cultured for 28-32h in special IVM media in order to get the matured oocytes. All the metaphase II (MII) oocytes were inseminated by means of intracytoplasmic sperm injection (ICSI). All embryos will be cultured to blastocyst stage and be vitrified.
Trial: NCT00569257
Drug: AEZS-108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion at a dose of 267 mg/sqm every 3 weeks, up to 6 treatment cycles
Trial: NCT04639804
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg tablet
Trial: NCT04639804
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg capsule
Trial: NCT00492024
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 380 mg Microcrystalline Cellulose
Trial: NCT03795922
Drug: MT10109L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT10109L will be injected into the GL.
Trial: NCT03795922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be injected into the GL.
Trial: NCT03387631
Drug: Artemether-Lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02351232
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no